ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer

被引:15
作者
Li, Chunhong [1 ]
Liu, Meiyan [1 ]
Yan, An [1 ]
Liu, Wei [1 ]
Hou, Junjun [1 ]
Cai, Li [1 ]
Dong, Xiaoqun [2 ,3 ]
机构
[1] Harbin Med Univ Canc Hosp, Dept Internal Med Oncol, Harbin 150040, Heilongjiang Pr, Peoples R China
[2] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Internal Med, Coll Med, Oklahoma City, OK 73104 USA
基金
中国国家自然科学基金;
关键词
Non-small cell lung cancer (NSCLC); Excision repair cross-complementing gene 1 (ERCC1); Survival; Cisplatin; PLATINUM-BASED CHEMOTHERAPY; MESSENGER-RNA EXPRESSION; PHASE-III TRIAL; ADJUVANT CHEMOTHERAPY; DNA-REPAIR; SURVIVAL; RRM1; GEMCITABINE; STATISTICS; MUTATIONS;
D O I
10.1007/s13277-014-2595-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Excision repair cross-complementing gene 1 (ERCC1) protein is proposed as a predictor for cisplatin efficacy in patients with non-small cell lung cancer (NSCLC). However, recent studies declare that ERCC1 is not associated with the response of platinum-based chemotherapy or clinical outcomes. The purpose of this study is to assess whether ERCC1 expression level is linked to cisplatin sensitivity and clinical outcomes in resected NSCLC patients. Paraffin-embedded cancer samples from 112 patients were used for immunohistochemical staining. Cancer cells isolated from fresh tumor tissues were used to determine the sensitivity to cisplatin by MTT assay. The association between ERCC1 expression and cisplatin sensitivity was tested by Spearman's rho test. The correlation of ERCC1 expression with clinicopathologic parameters was evaluated by the chi-square tests. The relationship between variables and survival was assessed by log-rank test. Overall survival (OS) and disease-free survival (DFS) curves were plotted by the Kaplan-Meier method. Cox proportional hazards model was used for multivariate analysis of survival. ERCC1 expression was significantly correlated with the sensitivity of cisplatin in vitro (p<0.01, r=0.37). ERCC1 was not associated with OS (p=0.17) or DFS (p=0.13) in patients with resected NSCLC. ERCC1 is not a sensible marker for the choice of treatment in clinical patients with resected NSCLC.
引用
收藏
页码:12707 / 12712
页数:6
相关论文
共 36 条
  • [1] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
    Aberle, Denise R.
    Adams, Amanda M.
    Berg, Christine D.
    Black, William C.
    Clapp, Jonathan D.
    Fagerstrom, Richard M.
    Gareen, Ilana F.
    Gatsonis, Constantine
    Marcus, Pamela M.
    Sicks, JoRean D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) : 395 - 409
  • [2] Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer - An analysis of National Cancer Institute of Canada and intergroup trial JBR. 10 and a review of the literature
    Alam, N
    Shepherd, FA
    Winton, T
    Graham, B
    Johnson, D
    Livingston, R
    Rigas, J
    Whitehead, M
    Ding, K
    Seymour, L
    [J]. LUNG CANCER, 2005, 47 (03) : 385 - 394
  • [3] RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
    Bepler, Gerold
    Kusmartseva, Irina
    Sharma, Swati
    Gautam, Ashish
    Cantor, Alan
    Sharma, Anupama
    Simon, George
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) : 4731 - 4737
  • [4] Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer
    Bepler, Gerold
    Williams, Charles
    Schell, Michael J.
    Chen, Wei
    Zheng, Zhong
    Simon, George
    Gadgeel, Shirish
    Zhao, Xiuhua
    Schreiber, Fred
    Brahmer, Julie
    Chiappori, Alberto
    Tanvetyanon, Tawee
    Pinder-Schenck, Mary
    Gray, Jhanelle
    Haura, Eric
    Antonia, Scott
    Fischer, Juergen R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) : 2404 - +
  • [5] Time to adjuvant chemotherapy and survival in non-small cell lung cancer A Population-Based Study
    Booth, Christopher M.
    Shepherd, Frances A.
    Peng, Yingwei
    Darling, Gail
    Li, Gavin
    Kong, Weidong
    Biagi, James J.
    Mackillop, William J.
    [J]. CANCER, 2013, 119 (06) : 1243 - 1250
  • [6] ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer
    Booton, Richard
    Ward, Tim
    Ashcroft, Linda
    Morris, Julie
    Heighway, Jim
    Thatcher, Nick
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (10) : 902 - 906
  • [7] ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
    Ceppi, P.
    Volante, M.
    Novello, S.
    Rapa, I.
    Danenberg, K. D.
    Danenberg, P. V.
    Cambieri, A.
    Selvaggi, G.
    Saviozzi, S.
    Calogero, R.
    Papotti, M.
    Scagliotti, G. V.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (12) : 1818 - 1825
  • [8] Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression:: A phase III trial in non-small-cell lung cancer
    Cobo, Manuel
    Isla, Dolores
    Massuti, Bartomeu
    Montes, Ana
    Miguel Sanchez, Jose
    Provencio, Mariano
    Vinolas, Nuria
    Paz-Ares, Luis
    Lopez-Vivanco, Guillermo
    Angel Munoz, Miguel
    Felip, Enriqueta
    Alberola, Vicente
    Camps, Carlos
    Domine, Manuel
    Sanchez, Jose Javier
    Sanchez-Ronco, Maria
    Danenberg, Kathleen
    Taron, Miquel
    Gandara, David
    Rosell, Rafael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) : 2747 - 2754
  • [9] Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group
    Fossella, F
    Pereira, JR
    von Pawel, J
    Pluzanska, A
    Gorbounova, V
    Kaukel, E
    Mattson, KV
    Ramlau, R
    Szczesna, A
    Fidias, P
    Millward, M
    Belani, CP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3016 - 3024
  • [10] ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer
    Friboulet, Luc
    Olaussen, Ken Andre
    Pignon, Jean-Pierre
    Shepherd, Frances A.
    Tsao, Ming-Sound
    Graziano, Stephen
    Kratzke, Robert
    Douillard, Jean-Yves
    Seymour, Lesley
    Pirker, Robert
    Filipits, Martin
    Andre, Fabrice
    Solary, Eric
    Ponsonnailles, Florence
    Robin, Angelique
    Stoclin, Annabelle
    Dorvault, Nicolas
    Commo, Frederic
    Adam, Julien
    Vanhecke, Elsa
    Saulnier, Patrick
    Thomale, Juergen
    Le Chevalier, Thierry
    Dunant, Ariane
    Rousseau, Vanessa
    Le Teuff, Gwenael
    Brambilla, Elisabeth
    Soria, Jean-Charles
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (12) : 1101 - 1110